Heparan sulfate proteoglycans in healthy and diseased systems

Wiley Interdisciplinary Reviews: Systems Biology and Medicine

Volumn 3, Issue 6, 2011, Pages 739-751

  Whitelock, John ^a   Melrose, James ^b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AGRIN; BETA GLUCURONIDASE; COLLAGEN TYPE 18; EXOSTOSIN 1; EXOSTOSIN-1; GLYPICAN; HEPARANASE; N ACETYLGLUCOSAMINYLTRANSFERASE; PERLECAN; PROTEOHEPARAN SULFATE; SYNDECAN;

ANIMAL; ANIMAL MODEL; ARTICLE; CLASSIFICATION; DRUG ANTAGONISM; GENETICS; METABOLISM; MOUSE; MOUSE MUTANT; MUSCULOSKELETAL DISEASE; MUSCULOSKELETAL SYSTEM; PATHOLOGY; PHENOTYPE;

AGRIN; ANIMALS; COLLAGEN TYPE XVIII; GLUCURONIDASE; GLYPICANS; HEPARAN SULFATE PROTEOGLYCANS; MICE; MICE, KNOCKOUT; MODELS, ANIMAL; MUSCULOSKELETAL DISEASES; MUSCULOSKELETAL SYSTEM; N-ACETYLGLUCOSAMINYLTRANSFERASES; PHENOTYPE; SYNDECANS;

MAMMALIA;

EID: 80053470097     PISSN: 19395094     EISSN: 1939005X     Source Type: Journal    
DOI: 10.1002/wsbm.149     Document Type: Article

References (137)

1. Forsberg E, Pejler G, Ringvall M, Lunderius C, Tomasini-Johansson B, Kusche-Gullberg M, Eriksson I, Ledin J, Hellman L, Kjellen L. Abnormal mast cells in mice deficient in a heparin-synthesizing enzyme. Nature 1999, 400:773-776.
2. Kjellen L. Glucosaminyl N-deacetylase/N-sulphotransferases in heparan sulphate biosynthesis and biology. Biochem Soc Trans 2003, 31:340-342.
3. Brown AJ, Alicknavitch M, D'Souza SS, Daikoku T, Kirn-Safran CB, Marchetti D, Carson DD, Farach-Carson MC. Heparanase expression and activity influences chondrogenic and osteogenic processes during endochondral bone formation. Bone 2008, 43:689-699.
4. Dong S, Wu XZ. Heparanase and hepatocellular carcinoma: promoter or inhibitor? World J Gastroenterol 2010, 16:306-311.
5. Fux L, Ilan N, Sanderson RD, Vlodavsky I. Heparanase: busy at the cell surface. Trends Biochem Sci 2009, 34:511-519.
6. Kram V, Zcharia E, Yacoby-Zeevi O, Metzger S, Chajek-Shaul T, Gabet Y, Muller R, Vlodavsky I, Bab I. Heparanase is expressed in osteoblastic cells and stimulates bone formation and bone mass. J Cell Physiol 2006, 207:784-792.
7. Szymczak M, Kuzniar J, Klinger M. The role of heparanase in diseases of the glomeruli. Arch Immunol Ther Exp (Warsz) 2010, 58:45-56.
8. Zcharia E, Jia J, Zhang X, Baraz L, Lindahl U, Peretz T, Vlodavsky I, Li JP. Newly generated heparanase knock-out mice unravel co-regulation of heparanase and matrix metalloproteinases. PLoS One 2009, 4:e5181.
9. Arikawa-Hirasawa E, Watanabe H, Takami H, Hassell JR, Yamada Y. Perlecan is essential for cartilage and cephalic development. Nat Genet 1999, 23:354-358.
10. Arikawa-Hirasawa E, Wilcox WR, Le AH, Silverman N, Govindraj P, Hassell JR, Yamada Y. Dyssegmental dysplasia, Silverman-Handmaker type, is caused by functional null mutations of the perlecan gene. Nat Genet 2001, 27:431-434.
11. Paine-Saunders S, Viviano BL, Zupicich J, Skarnes WC, Saunders S. Glypican-3 controls cellular responses to Bmp4 in limb patterning and skeletal development. Dev Biol 2000, 225:179-187.
12. Viviano BL, Silverstein L, Pflederer C, Paine-Saunders S, Mills K, Saunders S. Altered hematopoiesis in glypican-3-deficient mice results in decreased osteoclast differentiation and a delay in endochondral ossification. Dev Biol 2005, 282:152-162.
13. Ng A, Wong M, Viviano B, Erlich JM, Alba G, Pflederer C, Jay PY, Saunders S. Loss of glypican-3 function causes growth factor-dependent defects in cardiac and coronary vascular development. Dev Biol 2009, 335:208-215.
14. Li Q, Olsen BR. Increased angiogenic response in aortic explants of collagen XVIII/endostatin-null mice. Am J Pathol 2004, 165:415-424.
15. Moulton KS, Olsen BR, Sonn S, Fukai N, Zurakowski D, Zeng X. Loss of collagen XVIII enhances neovascularization and vascular permeability in atherosclerosis. Circulation 2004, 110:1330-1336.
16. Gotte M, Joussen AM, Klein C, Andre P, Wagner DD, Hinkes MT, Kirchhof B, Adamis AP, Bernfield M. Role of syndecan-1 in leukocyte-endothelial interactions in the ocular vasculature. Invest Ophthalmol Vis Sci 2002, 43:1135-1141.
17. Echtermeyer F, Streit M, Wilcox-Adelman S, Saoncella S, Denhez F, Detmar M, Goetinck P. Delayed wound repair and impaired angiogenesis in mice lacking syndecan-4. J Clin Invest 2001, 107:R9-R14.
18. Ishiguro K, Kadomatsu K, Kojima T, Muramatsu H, Nakamura E, Ito M, Nagasaka T, Kobayashi H, Kusugami K, Saito H, et al. Syndecan-4 deficiency impairs the fetal vessels in the placental labyrinth. Dev Dyn 2000, 219: 539-544.
19. Kaksonen M, Pavlov I, Voikar V, Lauri SE, Hienola A, Riekki R, Lakso M, Taira T, Rauvala H. Syndecan-3-deficient mice exhibit enhanced LTP and impaired hippocampus-dependent memory. Mol Cell Neurosci 2002, 21:158-172.
20. Ylikarppa R, Eklund L, Sormunen R, Kontiola AI, Utriainen A, Maatta M, Fukai N, Olsen BR, Pihlajaniemi T. Lack of type XVIII collagen results in anterior ocular defects. FASEB J 2003, 17:2257-2259.
21. Utriainen A, Sormunen R, Kettunen M, Carvalhaes LS, Sajanti E, Eklund L, Kauppinen R, Kitten GT, Pihlajaniemi T. Structurally altered basement membranes and hydrocephalus in a type XVIII collagen deficient mouse line. Hum Mol Genet 2004, 13:2089-2099.
22. Gautam M, Noakes PG, Moscoso L, Rupp F, Scheller RH, Merlie JP, Sanes JR. Defective neuromuscular synaptogenesis in agrin-deficient mutant mice. Cell 1996, 85:525-535.
23. Serpinskaya AS, Feng G, Sanes JR, Craig AM. Synapse formation by hippocampal neurons from agrin-deficient mice. Dev Biol 1999, 205:65-78.
24. Arikawa-Hirasawa E, Rossi SG, Rotundo RL, Yamada Y. Absence of acetylcholinesterase at the neuromuscular junctions of perlecan-null mice. Nat Genet 2002, 5:119-123.
25. Xu Z, Ichikawa N, Kosaki K, Yamada Y, Sasaki T, Sakai LY, Kurosawa H, Hattori N, Arikawa-Hirasawa E. Perlecan deficiency causes muscle hypertrophy, a decrease in myostatin expression, and changes in muscle fiber composition. Matrix Biol 2010, 29:461-470.
26. Cornelison DD, Wilcox-Adelman SA, Goetinck PF, Rauvala H, Rapraeger AC, Olwin BB. Essential and separable roles for Syndecan-3 and Syndecan-4 in skeletal muscle development and regeneration. Genes Dev 2004, 18:2231-2236.
27. Xu J, Park PW, Kheradmand F, Corry DB. Endogenous attenuation of allergic lung inflammation by syndecan-1. J Immunol 2005, 174:5758-5765.
28. Li Q, Park PW, Wilson CL, Parks WC. Matrilysin shedding of syndecan-1 regulates chemokine mobilization and transepithelial efflux of neutrophils in acute lung injury. Cell 2002, 111:635-646.
29. Schick BP. Serglycin proteoglycan deletion in mouse platelets: physiological effects and their implications for platelet contributions to thrombosis, inflammation, atherosclerosis, and metastasis. Prog Mol Biol Transl Sci 2010, 93:235-287.
30. Woulfe DS, Lilliendahl JK, August S, Rauova L, Kowalska MA, Abrink M, Pejler G, White JG, Schick BP. Serglycin proteoglycan deletion induces defects in platelet aggregation and thrombus formation in mice. Blood 2008, 111:3458-3467.
31. Niemann CU, Abrink M, Pejler G, Fischer RL, Christensen EI, Knight SD, Borregaard N. Neutrophil elastase depends on serglycin proteoglycan for localization in granules. Blood 2007, 109:4478-4486.
32. Ringvall M, Ronnberg E, Wernersson S, Duelli A, Henningsson F, Abrink M, Garcia-Faroldi G, Fajardo I, Pejler G. Serotonin and histamine storage in mast cell secretory granules is dependent on serglycin proteoglycan. J Allergy Clin Immunol 2008, 121:1020-1026.
33. Grujic M, Braga T, Lukinius A, Eloranta ML, Knight SD, Pejler G, Abrink M. Serglycin-deficient cytotoxic T lymphocytes display defective secretory granule maturation and granzyme B storage. J Biol Chem 2005, 280:33411-33418.
34. Lundequist A, Abrink M, Pejler G. Mast cell-dependent activation of pro matrix metalloprotease 2: a role for serglycin proteoglycan-dependent mast cell proteases. Biol Chem 2006, 387:1513-1519.
35. Rossi M, Morita H, Sormunen R, Airenne S, Kreivi M, Wang L, Fukai N, Olsen BR, Tryggvason K, Soininen R. Heparan sulfate chains of perlecan are indispensable in the lens capsule but not in the kidney. EMBO J 2003, 22:236-245.
36. Morita H, Yoshimura A, Inui K, Ideura T, Watanabe H, Wang L, Soininen R, Tryggvason K. Heparan sulfate of perlecan is involved in glomerular filtration. J Am Soc Nephrol 2005, 16:1703-1710.
37. Koziel L, Kunath M, Kelly OG, Vortkamp A. Ext1-dependent heparan sulfate regulates the range of Ihh signaling during endochondral ossification. Dev Cell 2004, 6:801-813.
38. Stickens D, Brown D, Evans GA. EXT genes are differentially expressed in bone and cartilage during mouse embryogenesis. Dev Dyn 2000, 218:452-464.
39. Stickens D, Zak BM, Rougier N, Esko JD, Werb Z. Mice deficient in Ext2 lack heparan sulfate and develop exostoses. Development 2005, 132:5055-5068.
40. Hecht JT, Hayes E, Haynes R, Cole WG, Long RJ, Farach-Carson MC, Carson DD. Differentiation-induced loss of heparan sulfate in human exostosis derived chondrocytes. Differentiation 2005, 73:212-221.
41. Pallerla SR, Lawrence R, Lewejohann L, Pan Y, Fischer T, Schlomann U, Zhang X, Esko JD, Grobe K. Altered heparan sulfate structure in mice with deleted NDST3 gene function. J Biol Chem 2008, 283:16885-16894.
42. Grobe K, Inatani M, Pallerla SR, Castagnola J, Yamaguchi Y, Esko JD. Cerebral hypoplasia and craniofacial defects in mice lacking heparan sulfate Ndst1 gene function. Development 2005, 132: 3777-3786.
43. Pallerla SR, Pan Y, Zhang X, Esko JD, Grobe K. Heparan sulfate Ndst1 gene function variably regulates multiple signaling pathways during mouse development. Dev Dyn 2007, 236:556-563.
44. Ringvall M, Ledin J, Holmborn K, van Kuppevelt T, Ellin F, Eriksson I, Olofsson AM, Kjellen L, Forsberg E. Defective heparan sulfate biosynthesis and neonatal lethality in mice lacking N-deacetylase/ N-sulfotransferase-1. J Biol Chem 2000, 275: 25926-25930.
45. Li JP, Gong F, Hagner-McWhirter A, Forsberg E, Abrink M, Kisilevsky R, Zhang X, Lindahl U. Targeted disruption of a murine glucuronyl C5-epimerase gene results in heparan sulfate lacking l-iduronic acid and in neonatal lethality. J Biol Chem 2003, 278:28363-28366.
46. Reijmers RM, Vondenhoff MF, Roozendaal R, Kuil A, Li JP, Spaargaren M, Pals ST, Mebius RE. Impaired lymphoid organ development in mice lacking the heparan sulfate modifying enzyme glucuronyl C5-epimerase. J Immunol 2010, 184:3656-3664.
47. Pan Y, Woodbury A, Esko JD, Grobe K, Zhang X. Heparan sulfate biosynthetic gene Ndst1 is required for FGF signaling in early lens development. Development 2006, 133:4933-4944.
48. Bullock SL, Fletcher JM, Beddington RS, Wilson VA. Renal agenesis in mice homozygous for a gene trap mutation in the gene encoding heparan sulfate 2-sulfotransferase. Genes Dev 1998, 12:1894-1906.
49. Crawford BE, Garner OB, Bishop JR, Zhang DY, Bush KT, Nigam SK, Esko JD. Loss of the heparan sulfate sulfotransferase, Ndst1, in mammary epithelial cells selectively blocks lobuloalveolar development in mice. PLoS One 2010, 5:e10691.
50. Fan G, Xiao L, Cheng L, Wang X, Sun B, Hu G. Targeted disruption of NDST-1 gene leads to pulmonary hypoplasia and neonatal respiratory distress in mice. FEBS Lett 2000, 467:7-11.
51. Otsuki S, Taniguchi N, Grogan SP, D'Lima D, Kinoshita M, Lotz M. Expression of novel extracellular sulfatases Sulf-1 and Sulf-2 in normal and osteoarthritic articular cartilage. Arthritis Res Ther 2008, 10:R61.
52. Otsuki S, Hanson SR, Miyaki S, Grogan SP, Kinoshita M, Asahara H, Wong CH, Lotz MK. Extracellular sulfatases support cartilage homeostasis by regulating BMP and FGF signaling pathways. Proc Natl Acad Sci U S A 2010, 107:10202-10207.
53. Li JP, Galvis ML, Gong F, Zhang X, Zcharia E, Metzger S, Vlodavsky I, Kisilevsky R, Lindahl U. In vivo fragmentation of heparan sulfate by heparanase overexpression renders mice resistant to amyloid protein A amyloidosis. Proc Natl Acad Sci U S A 2005, 102:6473-6477.
54. Zcharia E, Metzger S, Chajek-Shaul T, Aingorn H, Elkin M, Friedmann Y, Weinstein T, Li JP, Lindahl U, Vlodavsky I. Transgenic expression of mammalian heparanase uncovers physiological functions of heparan sulfate in tissue morphogenesis, vascularization, and feeding behavior. FASEB J 2004, 18:252-263.
55. Couchman JR. Transmembrane signaling proteoglycans. Annu Rev Cell Dev Biol 2010, 26:89-114.
56. Iozzo RV. Heparan sulfate proteoglycans: intricate molecules with intriguing functions. J Clin Invest 2001, 108:165-167.
57. Capurro MI, Xu P, Shi W, Li F, Jia A, Filmus J. Glypican-3 inhibits Hedgehog signaling during development by competing with patched for Hedgehog binding. Glypicans: proteoglycans with a surprise. Dev Cell 2008, 14:700-711.
58. Filmus J, Selleck SB. Glypicans: proteoglycans with a surprise. J Clin Invest 2001, 108:497-501.
59. Iglesias BV, Centeno G, Pascuccelli H, Ward F, Peters MG, Filmus J, Puricelli L, de Kier Joffe EB. Expression pattern of glypican-3 (GPC3) during human embryonic and fetal development. Histol Histopathol 2008, 23:1333-1340.
60. Alexopoulou AN, Multhaupt HA, Couchman JR. Syndecans in wound healing, inflammation and vascular biology. Int J Biochem Cell Biol 2007, 39:505-528.
61. Bernfield M, Kokenyesi R, Kato M, Hinkes MT, Spring J, Gallo RL, Lose EJ. Biology of the syndecans: a family of transmembrane heparan sulfate proteoglycans. Annu Rev Cell Biol 1992, 8:365-393.
62. Mythreye K, Blobe GC. Proteoglycan signaling co-receptors: roles in cell adhesion, migration and invasion. Cell Signal 2009, 21:1548-1558.
63. Melrose J, Hayes AJ, Whitelock JM, Little CB. Perlecan, the "jack of all trades" proteoglycan of cartilaginous weight-bearing connective tissues. Bioessays 2008, 30:457-469.
64. Whitelock JM, Melrose J, Iozzo RV. Diverse cell signaling events modulated by perlecan. Biochemistry 2008, 47:11174-11183.
65. Iozzo RV. Basement membrane proteoglycans: from cellar to ceiling. Nat Rev Mol Cell Biol 2005, 6: 646-656.
66. Chuang CY, Lord MS, Melrose J, Rees MD, Knox SM, Freeman C, Iozzo RV, Whitelock JM. Heparan sulfate-dependent signaling of fibroblast growth factor 18 by chondrocyte-derived perlecan. Biochemistry 2010, 49:5524-5532.
67. Melrose J, Roughley P, Knox S, Smith S, Lord M, Whitelock J. The structure, location, and function of perlecan, a prominent pericellular proteoglycan of fetal, postnatal, and mature hyaline cartilages. J Biol Chem 2006, 281:36905-36914.
68. Pufe T, Petersen WJ, Miosge N, Goldring MB, Mentlein R, Varoga DJ, Tillmann BN. Endostatin/ collagen XVIII-an inhibitor of angiogenesis-is expressed in cartilage and fibrocartilage. Matrix Biol 2004, 23:267-276.
69. Dong S, Cole GJ, Halfter W. Expression of collagen XVIII and localization of its glycosaminoglycan attachment sites. J Biol Chem 2003, 278:1700-1707.
70. Tsen G, Halfter W, Kroger S, Cole GJ. Agrin is a heparan sulfate proteoglycan. J Biol Chem 1995, 270:3392-3399.
71. Bezakova G, Ruegg MA. New insights into the roles of agrin. Nat Rev Mol Cell Biol 2003, 4:295-308.
72. Banyai L, Sonderegger P, Patthy L. Agrin binds BMP2, BMP4 and TGFβ1. PLoS One 2010, 5:e10758.
73. McCroskery S, Bailey A, Lin L, Daniels MP. Transmembrane agrin regulates dendritic filopodia and synapse formation in mature hippocampal neuron cultures. Neuroscience 2009, 163:168-179.
74. Hausser HJ, Ruegg MA, Brenner RE, Ksiazek I. Agrin is highly expressed by chondrocytes and is required for normal growth. Histochem Cell Biol 2007, 127:363-374.
75. Milstone LM, Hough-Monroe L, Kugelman LC, Bender JR, Haggerty JG. Epican, a heparan/chondroitin sulfate proteoglycan form of CD44, mediates cell-cell adhesion. J Cell Sci 1994, 107(Pt 11): 3183-3190.
76. Kolset SO, Tveit H. Serglycin-structure and biology. Cell Mol Life Sci 2008, 65:1073-1085.
77. Pejler G, Abrink M, Wernersson S. Serglycin proteoglycan: regulating the storage and activities of hematopoietic proteases. Biofactors 2009, 35:61-68.
78. Cummings RD. The repertoire of glycan determinants in the human glycome. Mol Biosyst 2009, 5:1087-1104.
79. Syu A, Ishiguro H, Inada T, Horiuchi Y, Tanaka S, Ishikawa M, Arai M, Itokawa M, Niizato K, Iritani S, et al. Association of the HSPG2 gene with neuroleptic-induced tardive dyskinesia. Neuropsychopharmacology 2010, 35:1155-1164.
80. Zhou Z, Wang J, Cao R, Morita H, Soininen R, Chan KM, Liu B, Cao Y, Tryggvason K. Impaired angiogenesis, delayed wound healing and retarded tumor growth in perlecan heparan sulfate-deficient mice. Cancer Res 2004, 64:4699-4702.
81. Chen K, Ohkubo Y, Shin D, Doetschman T, Sanford LP, Li H, Vaccarino FM. Decrease in excitatory neurons, astrocytes and proliferating progenitors in the cerebral cortex of mice lacking exon 3 from the Fgf2 gene. BMC Neurosci 2008, 9:94.
82. Jen YH, Musacchio M, Lander AD. Glypican-1 controls brain size through regulation of fibroblast growth factor signaling in early neurogenesis. Neural Dev 2009, 4:33.
83. Campos-Xavier AB, Martinet D, Bateman J, Belluoccio D, Rowley L, Tan TY, Baxova A, Gustavson KH, Borochowitz ZU, Innes AM, et al. Mutations in the heparan-sulfate proteoglycan glypican 6 (GPC6) impair endochondral ossification and cause recessive omodysplasia. Am J Hum Genet 2009, 84:760-770.
84. Echtermeyer F, Bertrand J, Dreier R, Meinecke I, Neugebauer K, Fuerst M, Lee YJ, Song YW, Herzog C, Theilmeier G, et al. Syndecan-4 regulates ADAMTS-5 activation and cartilage breakdown in osteoarthritis. Nat Med 2009, 15:1072-1076.
85. Cornelison DD, Filla MS, Stanley HM, Rapraeger AC, Olwin BB. Syndecan-3 and syndecan-4 specifically mark skeletal muscle satellite cells and are implicated in satellite cell maintenance and muscle regeneration. Dev Biol 2001, 239:79-94.
86. Gautam M, DeChiara TM, Glass DJ, Yancopoulos GD, Sanes JR. Distinct phenotypes of mutant mice lacking agrin, MuSK, or rapsyn. Brain Res Dev Brain Res 1999, 114:171-178.
87. Rotundo RL, Rossi SG, Kimbell LM, Ruiz C, Marrero E. Targeting acetylcholinesterase to the neuromuscular synapse. Chem Biol Interact 2005, 157-158:15-21.
88. Peng HB, Ali AA, Daggett DF, Rauvala H, Hassell JR, Smalheiser NR. The relationship between perlecan and dystroglycan and its implication in the formation of the neuromuscular junction. Cell Adhes Commun 1998, 5:475-489.
89. Arikawa-Hirasawa E, Le AH, Nishino I, Nonaka I, Ho NC, Francomano CA, Govindraj P, Hassell JR, Devaney JM, Spranger J, et al. Structural and functional mutations of the perlecan gene cause Schwartz-Jampel syndrome, with myotonic myopathy and chondrodysplasia. Am J Hum Genet 2002, 70:1368-1375.
90. Marneros AG, Keene DR, Hansen U, Fukai N, Moulton K, Goletz PL, Moiseyev G, Pawlyk BS, Halfter W, Dong S, et al. Collagen XVIII/endostatin is essential for vision and retinal pigment epithelial function. EMBO J 2004, 23:89-99.
91. Merry CL, Wilson VA. Role of heparan sulfate-2-O-sulfotransferase in the mouse. Biochim Biophys Acta 2002, 1573:319-327.
92. Lai JP, Sandhu DS, Shire AM, Roberts LR. The tumor suppressor function of human sulfatase 1 (SULF1) in carcinogenesis. J Gastrointest Cancer 2008, 39: 149-158.
93. Lemjabbar-Alaoui H, van Zante A, Singer MS, Xue Q, Wang YQ, Tsay D, He B, Jablons DM, Rosen SD. Sulf-2, a heparan sulfate endosulfatase, promotes human lung carcinogenesis. Oncogene 2010, 29:635-646.
94. Tran VM, Nguyen TK, Raman K, Kuberan B. Applications of isotopes in advancing structural and functional heparanomics. Anal Bioanal Chem 2011, 399:559-570.
95. Lamanna WC, Kalus I, Padva M, Baldwin RJ, Merry CL, Dierks T. The heparanome-the enigma of encoding and decoding heparan sulfate sulfation. J Biotechnol 2007, 129:290-307.
96. Howell WH, Holt E. Two new factors in blood coagulation-heparin and pro-antithrombin. Am J Physiol 1918, 47:328-341.
97. Jorpes E. The chemistry of heparin. Biochem J 1935, 29:1817-1830.
98. Linhardt RJ, Gunay NS. Production and chemical processing of low molecular weight heparins. Semin Thromb Hemost 1999, 25(suppl 3):5-16.
99. Lindahl U, Backstrom G, Thunberg L, Leder IG. Evidence for a 3-O-sulfated d-glucosamine residue in the antithrombin-binding sequence of heparin. Proc Natl Acad Sci U S A 1980, 77:6551-6555.
100. Casu B, Guerrini M, Torri G. Structural and conformational aspects of the anticoagulant and anti-thrombotic activity of heparin and dermatan sulfate. Curr Pharm Des 2004, 10:939-949.
101. Shworak NW, Kobayashi T, Agostini A, Smits NC. Anticoagulant heparan sulfate to not clot-or not? Prog Mol Biol Transl Sci 2010, 93:153-178.
102. Dredge K, Hammond E, Davis K, Li CP, Liu L, Johnstone K, Handley P, Wimmer N, Gonda TJ, Gautam A, et al. The PG500 series: novel heparan sulfate mimetics as potent angiogenesis and heparanase inhibitors for cancer therapy. Invest New Drugs 2010, 28:276-283.
103. Khasraw M, Pavlakis N, McCowatt S, Underhill C, Begbie S, de Souza P, Boyce A, Parnis F, Lim V, Harvie R, et al. Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer. Ann Oncol 2010, 21:1302-1307.
104. Liu CJ, Lee PH, Lin DY, Wu CC, Jeng LB, Lin PW, Mok KT, Lee WC, Yeh HZ, Ho MC, et al. Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: a randomized phase II trial for safety and optimal dosage. J Hepatol 2009, 50:958-968.
105. French MM, Gomes RR, Jr. Timpl R, Hook M, Czymmek K, Farach-Carson MC, Carson DD. Chondrogenic activity of the heparan sulfate proteoglycan perlecan maps to the N-terminal domain I. J Bone Miner Res 2002, 17:48-55.
106. Jha AK, Yang W, Kirn-Safran CB, Farach-Carson MC, Jia X. Perlecan domain I-conjugated, hyaluronic acid-based hydrogel particles for enhanced chondrogenic differentiation via BMP-2 release. Biomaterials 2009, 30:6964-6975.
107. Yang W, Gomes RR, Brown AJ, Burdett AR, Alicknavitch M, Farach-Carson MC, Carson DD. Chondrogenic differentiation on perlecan domain I, collagen II, and bone morphogenetic protein-2-based matrices. Tissue Eng 2006, 12:2009-2024.
108. Yang WD, Gomes RR, Alicknavitch M, Farach-Carson MC, Carson DD. Perlecan domain-1 promotes fibroblast growth factor-2 delivery in collagen I fibril scaffolds. Tissue Eng 2005, 11:76-89.
109. Costell M, Mann K, Yamada Y, Timpl R. Characterization of recombinant perlecan domain I and its substitution by glycosaminoglycans and oligosaccharides. Eur J Biochem 1997, 243:115-121.
110. Groffen AJ, Buskens CA, Tryggvason K, Veerkamp JH, Monnens LA, van den Heuvel LP. Expression and characterization of human perlecan domains I and II synthesized by baculovirus-infected insect cells. Eur J Biochem 1996, 241:827-834.
111. Muthusamy A, Cooper CR, Gomes RR Jr. Soluble perlecan domain I enhances vascular endothelial growth factor-165 activity and receptor phosphorylation in human bone marrow endothelial cells. BMC Biochem 2010, 11:43.
112. Brown JC, Sasaki T, Gohring W, Yamada Y, Timpl R. The C-terminal domain V of perlecan promotes β1 integrin-mediated cell adhesion, binds heparin, nidogen and fibulin-2 and can be modified by glycosaminoglycans. Eur J Biochem 1997, 250:39-46.
113. Farach-Carson MC, Brown AJ, Lynam M, Safran JB, Carson DD. A novel peptide sequence in perlecan domain IV supports cell adhesion, spreading and FAK activation. Matrix Biol 2008, 27:150-160.
114. Costell M, Sasaki T, Mann K, Yamada Y, Timpl R. Structural characterization of recombinant domain II of the basement membrane proteoglycan perlecan. FEBS Lett 1996, 396:127-131.
115. Schulze B, Mann K, Battistutta R, Wiedemann H, Timpl R. Structural properties of recombinant domain III-3 of perlecan containing a globular domain inserted into an epidermal-growth-factor-like motif. Eur J Biochem 1995, 231:551-556.
116. Schulze B, Sasaki T, Costell M, Mann K, Timpl R. Structural and cell-adhesive properties of three recombinant fragments derived from perlecan domain III. Matrix Biol 1996, 15:349-357.
117. Dolan M, Horchar T, Rigatti B, Hassell JR. Identification of sites in domain I of perlecan that regulate heparan sulfate synthesis. J Biol Chem 1997, 272:4316-4322.
118. Smith SM, West LA, Govindraj P, Zhang X, Ornitz DM, Hassell JR. Heparan and chondroitin sulfate on growth plate perlecan mediate binding and delivery of FGF-2 to FGF receptors. Matrix Biol 2007, 26:175-184.
119. Tapanadechopone P, Hassell JR, Rigatti B, Couchman JR. Localization of glycosaminoglycan substitution sites on domain V of mouse perlecan. Biochem Biophys Res Commun 1999, 265:680-690.
120. Graham LD, Whitelock JM, Underwood PA. Expression of human perlecan domain I as a recombinant heparan sulfate proteoglycan with 20-kDa glycosaminoglycan chains. Biochem Biophys Res Commun 1999, 256:542-548.
121. Kvist AJ, Johnson AE, Morgelin M, Gustafsson E, Bengtsson E, Lindblom K, Aszodi A, Fassler R, Sasaki T, Timpl R, et al. Chondroitin sulfate perlecan enhances collagen fibril formation. Implications for perlecan chondrodysplasias. J Biol Chem 2006, 281: 33127-33139.
122. Sasaki T, Costell M, Mann K, Timpl R. Inhibition of glycosaminoglycan modification of perlecan domain I by site-directed mutagenesis changes protease sensitivity and laminin-1 binding activity. FEBS Lett 1998, 435:169-172.
123. Knox S, Fosang AJ, Last K, Melrose J, Whitelock J. Perlecan from human epithelial cells is a hybrid heparan/chondroitin/keratan sulfate proteoglycan. FEBS Lett 2005, 579:5019-5023.
124. Chakravarti S, Horchar T, Jefferson B, Laurie GW, Hassell JR. Recombinant domain III of perlecan promotes cell attachment through its RGDS sequence. J Biol Chem 1995, 270:404-409.
125. Kokenyesi R, Silbert JE. Formation of heparan sulfate or chondroitin/dermatan sulfate on recombinant domain I of mouse perlecan expressed in Chinese hamster ovary cells. Biochem Biophys Res Commun 1995, 211:262-267.
126. Ellis AL, Pan W, Yang G, Jones K, Chuang C, Whitelock JM, Decarlo AA. Similarity of recombinant human perlecan domain 1 by alternative expression systems bioactive heterogenous recombinant human perlecan D1. BMC Biotechnol 2010, 10:66.
127. Gandhi NS, Mancera RL. The structure of glycosaminoglycans and their interactions with proteins. Chem Biol Drug Des 2008, 72:455-482.
128. Kirn-Safran C, Farach-Carson MC, Carson DD. Multifunctionality of extracellular and cell surface heparan sulfate proteoglycans. Cell Mol Life Sci 2009, 66:3421-3434.
129. Ori A, Wilkinson MC, Fernig DG. The heparanome and regulation of cell function: structures, functions and challenges. Front Biosci 2008, 13:4309-4338.
130. Schultz GS, Wysocki A. Interactions between extracellular matrix and growth factors in wound healing. Wound Repair Regen 2009, 17:153-162.
131. Buono M, Cosma MP. Sulfatase activities towards the regulation of cell metabolism and signaling in mammals. Cell Mol Life Sci 2010, 67:769-780.
132. Fux L, Ilan N, Sanderson RD, Vlodavsky I. Heparanase: busy at the cell surface. Trends Biochem Sci 2009, 34:511-519.
133. Multhaupt HA, Yoneda A, Whiteford JR, Oh ES, Lee W, Couchman JR. Syndecan signaling: when, where and why? J Physiol Pharmacol 2009, 60(suppl 4):31-38.
134. Gorsi B, Merry SE. Tinkering with heparan sulfate sulfation to steer development. Trends Cell Biol 2007, 17:173-177.
135. Raman K, Kuberan B. Chemical tumor biology of heparan sulfate proteoglycans. Curr Chem Biol 2010, 4:20-31.
136. Bishop JR, Schuksz M, Esko JD. Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature 2007, 446:1030-1037.
137. Whitelock JM, Iozzo RV. Heparan sulfate: a complex polymer charged with biological activity. Chem Rev 2005, 105:2745-2764.